LINCOLN, Neb., Oct. 14, 2010 (GLOBE NEWSWIRE) -- A research report has been issued by Market Advisors, Inc. "Fundamental Analysis for Today's Investments" on Weikang Bio-Technology Group Company, Inc. (OTCBB:WKBT). To view the report, please go our web site at .
According to the report, China is the 8th largest pharmaceutical market in the world and is forecast to become the 5th largest in 2010 and the largest by 2050. Our intermediate term target price is $6.05.
About Weikang Bio-Technology Group, Company, Inc.
WKBT is principally engaged in developing, manufacturing and distributing Traditional Chinese Medicine (TCM) and health and nutritional supplements in China, in compliance with requisite Chinese licenses and approvals.
About Market Advisors, Inc.
Officers of Market Advisors, Inc. have been in business since 1983 and have provided stock market research for their clients since 1985. Company officials have often been quoted in a wide array of financial publications such as the Wall Street Journal, Investors Business Daily, Barron's, Forbes Magazine and The Dick Davis Digest to name a few.
The information and opinions in this analyst report were prepared by Market Advisors, Inc. and Associates. (located in Nebraska) who does receive fees for services including preparation of this report. This is not an offer to buy or sell securities nor should this report be construed as investment advice. Information or statements are subject to numerous risks and uncertainties that cause such statements not to prove accurate. Market Advisors, Inc. does not disseminate, nor is it liable for the dissemination by any third party of this analyst report
For further corporate information from WKBT, Inc, please visit:
CONTACT: Weikang Bio-Technology Group Co., Inc. Investor Relations (310)-819-2948 Market Advisors, Inc. Doug Wetzel (308) - 385-4991 dougwetz@kdsi.net
